Live Breaking News & Updates on Raymond Stevens

Stay updated with breaking news from Raymond stevens. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Will Oral Weight-Loss Drugs Break Open an Already Lucrative Market?

Now in Phase III with its small molecule orforglipron, Eli Lilly is leading the oral GLP-1 race against Novo Nordisk, Pfizer, Roche and others. ....

San-francisco , California , United-states , Americans , Novo-wegovy , Eli-lilly , Raymond-stevens , Michael-glickman , Taylor-tieden , Graig-suvannavejh , Levi-garraway , Lilly-zepbound

Carolyn Barnett | Obituary | Ottumwa Daily Courier

Carolyn Barnett passed away. This is the full obituary where you can share condolences and memories. Published in the Ottumwa Daily Courier on 2024-02-02. ....

Ottumwa , Iowa , United-states , New-york , Good-samaritan-center , Illinois , Sylvan-woods , Chicago , Memorial-lawn-cemetery , Mel-kendall , Raymond-stevens , Chester-paulson

Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement

Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

United-states , American , John-evans , Simeon-george , Christopher-anzalone , Vijay-pande , Lilly-mounjaro , Bristol-myers , Kyle-rasbach , Sekar-kathiresan , Tema-etfs , Andreessen-horowitz

Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement

Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Christopher-anzalone , Kyle-rasbach , John-evans , Andreessen-horowitz , Arnon-rosenthal , Clene-nanomedicine , Alector-rosenthal , Simeon-george , Rob-etherington , Lilly-mounjaro

Phase IIa data re-Structure hopes in oral GLP-1 effort

Given what CEO Raymond Stevens called a space that’s “evolving extremely rapidly,” Structure Therapeutics Inc. chose – rather than wait for next year’s 12-week data – to unblind the eight-week obesity findings with GSBR-1290, an oral glucagon-like peptide-1 (GLP-1) agonist for which the firm also provided a phase IIa update in patients with type 2 diabetes. ....

Raymond-stevens , Structure-therapeutics-inc , Gsbr-1290 , Structure-therapeutics-inc , Glp-1 , Type-2-diabetes , Glucagon-like-peptide-1-agonist , Eli-lilly-and-co , Orforglipron ,